Illumina Expands Genomic Discovery Alliance with Regeneron, Adds Proteomics Data
Event summary
- Illumina's Alliance for Genomic Discovery (AGD) adds Regeneron Genetics Center as its tenth member, expanding the dataset to 312,000 whole genomes.
- AGD introduces a new dataset of 50,000 whole genomes paired with proteomic data, with GSK as a lead participant.
- Illumina's acquisition of SomaLogic proteomics technologies enhances AGD's multiomics capabilities.
- AGD began sequencing in January 2023 and has already enabled discoveries in autoimmune disease and obesity.
The big picture
Illumina's expansion of the AGD alliance with Regeneron and the addition of proteomics data underscores the growing importance of multiomic approaches in drug discovery. This move aligns with broader industry trends towards leveraging large-scale genomic and proteomic datasets to identify high-confidence drug targets and optimize clinical trials. The inclusion of major pharma players like GSK and Amgen highlights the strategic value of these datasets in accelerating therapeutic development.
What we're watching
- Data Integration
- How the integration of proteomics with genomics will accelerate target discovery and therapy development.
- Industry Collaboration
- Whether the AGD alliance can sustain its momentum and expand further with additional pharma partners.
- Regulatory Dynamics
- The pace at which regulatory approvals for genomics-based therapies will advance with the enhanced AGD dataset.
Related topics